July 2022

Biopharmaceutical Development Program Produces Personalized Anticancer Medicine for Young People with Cancer

Chimeric antigen receptor (CAR) T cell therapy is a hot topic in healthcare. Successfully used to treat certain aggressive blood cancers for about a decade now, CAR T cell therapy is capturing the growing interest of oncologists who would like to harness its power to use against other cancer types. At Frederick National Laboratory, the Biopharmaceutical Development Program—a specialized team manufacturing experimental biotherapeutics for NCI—is at the center of an effort to develop CAR T therapies that will expand cancer treatment options, particularly for pediatric malignancies.

Spring Research Festival Recap and Award Winners

One of the annual rites of spring at the National Cancer Institute at Frederick returned in April, when hundreds of members of the Ft. Detrick and Frederick National Laboratory community participated in the virtual Spring Research Festival. The event was co-sponsored by the United States Army Medical Research and Development Command (USAMRDC) and the Military & Health Research Foundation (MHRF). 

Research Donor Program Makes a Big Impact with Small Samples

Look at your fingernails. What comes to mind? Now look at the veins in your arms. What about them? Odds are the words “critical” and “historic” aren’t your first thoughts, but they’d be an apt description. At NCI at Frederick and Frederick National Laboratory, nail clippings and blood specimens are two ways to make a difference in scientific research.

Nurturing the Science Talent Pipeline

Mark Twain once said that the secret to getting ahead is getting started. A group of Frederick High School (FHS) students clearly took that advice to heart when they jumped at the chance to learn more about careers in science, including the Werner H. Kirsten Student Internship Program at the National Cancer Institute (NCI) at Frederick and Frederick National Laboratory (FNL).

‘A Remarkable Life’: In Memory of Joost Oppenheim

Joost “Joe” Oppenheim, M.D., senior investigator and head of the Cellular Immunology Section in the Cancer Innovation Laboratory, passed away in May. He was one of the longest-tenured scientists at NCI at Frederick. Among his many accomplishments, he has been called “the Father of Cytokines” for his pioneering role in establishing the field of cytokine research in immunology.